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Electrochemiluminescent sensors as a screening
strategy for psychoactive substances within
biological matrices†
Kelly Brown, Charlotte Jacquet, Julien Biscay, Pamela Allan and Lynn Dennany *
With the rapid growth and appearance of novel psychoactive substances (NPS) onto the global drug
market, the need for alternative screening methodologies for implementation within clinical environments
is substantial. The immunoassay methods currently in use are inadequate for this new drug trend with the
potential for misdiagnosis and subsequent administration of incorrect patient treatment increased. This
contribution illustrates a strong proof-of-concept for the use of electrochemiluminescence (ECL) as a
screening methodology for NPS within biological fluids, using the hallucinogen scopolamine as a model
compound. A low cost, easy-to-use and portable sensor has been developed and successfully employed
for the detection of scopolamine at clinically relevant concentrations within a variety of biological
matrices, including human pooled serum, urine, artificial saliva and sweat, without any prior sample
preparation required. Moreover, assessment of the sensor’s potential as a point-of-care wearable device
was performed with sample collection from the surface of skin, demonstrating its capability for the quali-
tative identification of scopolamine despite collection of only minimal volumes off the skins surface. The
developed sensor described herein exhibits a strong proof-of-concept for the employment of such ECL
sensors as point-of-care devices, where the sensors ease of use and removal of time-consuming and
complex sample preparation methods will ultimately increase its usability by physicians, widening the
avenues where ECL sensors could be employed.
Introduction
Despite global implementation of increased legislative controls
to negate the use of novel psychoactive substances (NPS), they
remain prevalent both within the drug community and
market. NPS are typically designed to mimic the effects of tra-
ditional illicit substances but with an altered chemical struc-
ture, they were frequently outwith the control of current drug
legislation. Unsurprisingly, they grew in popularity amongst
users as a result of their accessibility.1–3 Despite their design
to mimic the effects of traditional drugs they are often found
to have unexpected and unwanted side effects. Currently, there
is limited knowledge regarding the pharmacological or phar-
macokinetic mechanisms of these substances; furthermore,
the continuous growth of NPS structural variations make it
almost impossible for authorities or practitioners to maintain
a working knowledge. The lack of understanding regarding the
pharmacokinetics of these substances is a significant problem;
with no information on their bioavailability, elimination half-
life, psychoactive effects, potency and toxicity available, life
threatening side effects and fatalities are common.4–6
One of the most notable issues related to NPS use is the
current lack of adequate screening protocols. The immuno-
assay methods typically utilised for screening of traditional
illicit substances, particularly within emergency rooms, are
not adequate for the detection of NPS. Often generating a
“false negative” or a “false positive” result, indicating the con-
sumption of a traditional illicit substance rather than an NPS,
as a result of the structure similarities or pharmacological
targets of NPS to traditional drugs. As such clinicians, toxicolo-
gists, emergency physicians and forensic practitioners have
been required to turn to alternative techniques for screening
of these substances. However, the alternative techniques avail-
able often include laborious and expensive detection methods
utilising mass spectrometry, a technique not suited for screen-
ing methods, especially when combined with the rapid appear-
ance of new NPS and lack of reference materials available for
their identification.4–7 This is especially relevant when consid-
ering the availability of such methods to emergency room
physicians. Mass spectrometry is not only expensive to
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perform and maintain, but requires skilled personnel, time
consuming sample preparation and available reference stan-
dards, all of which are not commonly available within a typical
emergency room. Moreover, physicians require a rapid answer
to determine patient treatment to ensure any further health
risks are minimised. As such, there is an urgent requirement
for new screening methodologies to address this gap.
Although required for a number of fields, there is particular
interest to focus upon methodologies appropriate for phys-
icians, where the requirement for ease-of-use, low cost and
rapid analysis is key.
Electrochemiluminescence (ECL) may hold a viable solu-
tion to this problem. ECL is a powerful technique with
increased development in recent years resulting in its wide
application across a number of different fields. ECL and other
electrochemical (EC) based techniques have become popular
within medical device and bioanalytical fields, largely owing to
their significant benefits over the more traditional
techniques.8–11 Primarily ECL and EC offer simplified instru-
mentation, increased operational simplicity and improved sen-
sitivity. Uniquely the luminescence generated by ECL is con-
trolled via the application of an applied external potential,
negating the need for an external light source in contrast to
alternative luminescence techniques. Removing this require-
ment allows for compact and lightweight instrumentation,
ideal for portable or point-of-care devices. Furthermore, the
cost of ECL instrumentation over the traditional techniques of
gas chromatography mass spectrometry (GC-MS) or liquid
chromatography mass spectrometry (LC-MS), required for the
identification of NPS such as scopolamine, is drastically
decreased. Not only is the initial outlay cost of instrumentation
vastly decreased, the maintenance and operational costs are
significantly lower and do not require a dedicated instrument
suite. In addition the minimal sample preparation and rapid
analysis times, intrinsic to ECL, ensure it satisfies all require-
ments for use by emergency room physicians.8–10,12 ECL based
sensors therefore hold significant potential as viable alterna-
tives to current screening techniques within emergency rooms,
particularly for NPS but also for the screening of the tra-
ditional illicit substances.
Scopolamine, a naturally occurring tropane alkaloid, is pro-
duced by members of the solanaceous family. Much like atro-
pine, its sister tropane alkaloid and biosynthetic precursor,
scopolamine has a history of recreational abuse due to its
anticholinergic hallucinogenic effects. Despite its hallucino-
genic properties scopolamine remains largely unregulated in a
number of countries, where the tropane alkaloid producing
plants are easily accessible, found even within domestic
gardens.13 Scopolamine is not only utilised for its hallucino-
genic effects, but also for the its suspected aphrodisiac,
amnesic and submissive effects on the user. These properties
are likely related to the recent increase in the use of scopola-
mine for drug facilitate crimes, including sexual assaults, rob-
beries and attempted murder.13–18 Scopolamine’s often
unknown toxicity poses an increased risk to the user, with
unintentional poisonings and fatalities commonly reported
despite the low amounts consumed. This was apparent in
2009, when an epidemic of scopolamine poisonings were
reported in Oslo after the date-rape drug Rohypnol was adult-
erated with the tropane alkaloid;17 in 2018, a number of drug
facilitate crimes in Spain were also found to involve scopola-
mine.19 Furthermore, the use of scopolamine as an incapaci-
tating drug has been utilised among the South-America
countries for decades.13–17 Scopolamine’s reported half-life is
approximately 1 hour, reaching its maximum concentration
approximately 20 minutes after ingestion of a therapeutic
dose, equivalent to a 0.5 mg tablet.20 One of the significant
challenges when investigating the use of illicit substances
within criminal activity, such as drug facilitated sexual assault,
is the rapid metabolism and excretion of the compounds,
making their detection after the matter extremely challenging.
Under emergency room scenarios however, with patients pre-
senting with symptoms, it is probable that such substances are
still within the detection window. Despite limited human
studies on the pharmacology and pharmacokinetics of scopo-
lamine, it has been detected within the urine of different
mammals between 24 to 106 hours following ingestion with a
wide range of dosage percentages observed across different
species.14,20,21 However, these animal studies fail to provide
the required knowledge on the excretion and metabolism path-
ways of scopolamine.14,20,21 The few human studies available
indicate that scopolamine is rapidly removed from the blood
and distributed around the body prior to liver metabolism,
where less than 5% of the parent compound is renally excreted
with, on average, an 8-hour half-life. Secondary drug excretion
of scopolamine is suspected with reports of the parent com-
pound found within hair, faeces and breath.20–22
With scopolamine abuse increasing a screening method-
ology capable of offering rapid detection is thus necessary.
This contribution discusses the use of a basic electrochemilu-
minescent sensor developed utilising screen-printed electro-
des, which offers rapid detection with minimal sample prepa-
ration and volumes at a low cost. For the first time the ability
to detect scopolamine not only via ECL but also within
complex biological matrices including, human serum, urine,
artificial saliva and artificial sweat has been achieved. What’s
more, successful replication of sensor application to the
surface of skin was achieved and despite significantly low
volumes of the hallucinogen present an easily identifiable
signal was observed. By removing the requirement for sample
preparation of biological fluids prior to analysis, it is hoped
that such a sensor would be ideal for implementation within
emergency rooms, although also appropriate for a range of
different fields, where physicians would be able to perform
analysis bedside obtaining the rapid answers they require for
patient treatment. A strong proof-of-concept for not only the
developed sensor but for the use of ECL based devices for
employment as point-of-care or in-field sensors, has been
demonstrated. These sensors could be easily used outwith a
laboratory environment by non-experts. The cost of this ana-
lysis in comparison to the mass spectrometry techniques cur-
rently employed for screening of NPS, such as scopolamine, is
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a significant advantage of such a design and stands to offer a
viable alternative screening methodology which currently does
not exist.
Experimental
Materials and reagents
Tris (2,2′-bipyridyl) – dichlororuthenium(II) hexahydrate ([Ru
(bpy)3]
2+), (−)-scopolamine hydrobromide trihydrate, lithium
perchlorate (LiClO4), urea, lactic acid, human pooled serum,
Surine™ and 117 Nafion (∼5% mixture of lower aliphatic alco-
hols and water) were purchased from Sigma-Aldrich. Absolute
EtOH, acetic acid, aluminium chloride (AlCl4) and NaCl were
purchased from VWR Chemicals. All chemicals were used as
received. All solutions were prepared in Milli-Q water (18 mΩ
cm−1). Artificial saliva (Bioténe® oral balance gel) and syn-
thetic skin were commercially purchased and used as received.
Instrumentation
In brief, a combination of a CH instrument model 760D
electrochemical analyser and Hamamatsu H10723-20 photo-
multiplier tube (PMT) were used for all electrochemical and
photoluminescence measurements. GSI Technologies
Electrochemical carbon screen printed electrodes (SPE) with a
4 mm carbon working electrode, carbon counter electrode and
Ag paste quasi-reference electrode were used throughout with
a maximum of 100 µL sample volume. A full description of the
instrumentation employment can be found within our prior
publications.23,24
Fabrication of [Ru(bpy)3]
2+/Nafion ECL sensor
The ECL sensor was fabricated using the same procedure pre-
viously described within Brown et al.23,24. In brief this com-
prised of modification of the working electrode surface via
drop-casting 7 µL of a 0.5 mM [Ru(bpy)3]
2+ and 0.2% Nafion
film in a 50 : 50 EtOH : H2O solvent system. Once prepared the
sensors were left to air dry under darkness for 2 hours. Prior
to sample measurements, to ensure a stable signal was
achieved, electrodes were pre-conditioned by performing three
subsequent CV scans over the potential range of interest
within the electrolyte solution. For biological fluid analysis
preconditioning was performed within the respective matrix.
For off-skin sample analysis no preconditioning was
performed.
Preparation of biological samples
All samples were prepared via spiking of the selected matrix
with the required volume of 5 mM scopolamine hydrobromide
prepared in H2O to produce the desired concentration. Human
pooled serum samples were stored at −80 °C and fully
defrosted at room temperature prior to spiking and measure-
ment. Artificial sweat was prepared following the ISO 3610-
2 guidance.25,26 Artificial saliva and synthetic urine were com-
mercially purchased and spiked with scopolamine as required.
Results and discussion
Detection of scopolamine via ECL
The ruthenium sensor utilised within this current study has
been previously optimised and subsequently characterised
within our prior publications.24,27 The sensor was observed to
exhibit the same electrochemical behaviour as previously
observed and hence is consistent with a typical Nafion-[Ru
(bpy)3]
2+ sensor.23,28–30 Tropane alkaloids, scopolamine and
atropine, have demonstrated the ability to reliably behave as
co-reactants producing ECL through the oxidative-reduction
pathway.23,24,31 As previously observed for atropine,24 scopola-
mine’s limited redox activity, results in minimal oxidation of
the species at unmodified electrode surfaces. At significantly
high concentrations a measurable oxidation signal can be
obtained, with oxidation occurring at ∼1.3 V vs. Ag, refer to
Fig. S1.† At the concentrations of interest however, direct
electrochemical oxidation is not sufficient for viable detection
methods. However, in the presence of [Ru(bpy)3]
2+, mediated
oxidation of the tropane group via the electro-generated Ru3+
species facilities light emission through the oxidative-
reduction pathway with a maximum ECL intensity observed at
∼0.9 V, see Fig. 1. The ECL mechanism undertaken by scopola-
mine is believed to follow a similar pathway to that observed
in the analytical studies of other structurally similar amine
species.23,32,33 Currently there is limited literature available on
the electrochemical detection of scopolamine itself. Da Costa
Oliveira et al.34 and Florea et al.,35 have previously reported the
direct electrochemical detection of scopolamine utilising
boron doped diamond and graphite screen printed electrodes
respectively. To date the detection of scopolamine via ECL has
largely been achieved through the employment of a prior sep-
aration strategy,36–38 with its use as a direct detection method
minimal.23,24
The structural similarities, typically indistinguishable oxi-
dation potentials and chemically irreversible electro-oxidation
of scopolamine generating formaldehyde, suggests that it
Fig. 1 ECL response of 0.1 M LiClO4 (blue) and 50 μM scopolamine
hydrobromide in 0.1 M LiClO4 (pink) at the [Ru(bpy)3]
2+
film modified
carbon screen printed working electrode with a scan rate of 100 mV s−1
across a potential range of 0.5 ≤ E ≥ 1.3 V vs. Ag at a PMT setting of 400
V.
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follows the same oxidative N-dealkylation mechanism as pro-
posed for atropine.23 This mechanism is based upon those
observed for tropanes39 and tertiary aliphatic amines40 and is
responsible for the ECL emission of scopolamine. The irrevers-
ible oxidation observed can be attributed to the electrolytic
degradation of scopolamine, forming a secondary amine
species at the tropane ring (norscopolamine) alongside formal-
dehyde. The oxidative-reduction mechanism proposed is sum-
marised in Scheme 1 and within eqn (1)–(5). The Ru3+ species
generated at the electrode surface during the forward potential
sweep (1) is required for the subsequent mediated oxidation of
scopolamine following (2), which generates the highly redu-
cing intermediate scopolamine• (a neutral radical species) (3).
This scopolamine radical (b) then undergoes homogenous
electron transfer with the remaining Ru3+ species to produce
the excited Ru2+* species, which upon relaxation emits a
photon of a characteristic wavelength. Following this hom-
ogenous electron transfer reaction, the imminium cation (c)
formed decomposes via hydrolysis and subsequent
N-dealkylation generating formaldehyde and the secondary
amine species, norscopolamine (e).
½RuðbpyÞ32þ  e $ ½RuðbpyÞ33þ ð1Þ
½RuðbpyÞ33þþ Scopolamine
! ½RuðbpyÞ32þ þ Scopolamine•þ
ð2Þ
Scopolamine•þ Ð Scopolamine• ð3Þ
½RuðbpyÞ33þþ Scopolamine• ! ½RuðbpyÞ32þ*
þ norscopolamineþ formaldehyde ð4Þ
½RuðbpyÞ32þ ! ½RuðbpyÞ32þ þ hν ð5Þ
The dependence of signal intensity with sample pH for ECL
analysis is dictated by the molecules’ dissociation mechanism.
pH determines whether the oxidizable form of the molecule is
dominant under different pH conditions. Previously we have
reported on the trend observed for atropine’s ECL intensity
with varying pH.27 As expected scopolamine displayed a
similar trend as seen for atropine and other structurally
similar amine species, refer to Fig. 2.23,24,29,41 As such, the
maximum ECL intensity was obtained at pH 8 close to the
compounds pKa of 7.75.
42 Furthermore measurable signals
were obtained across the entire pH range investigated for sco-
polamine, although to varying intensities.24 The ability to
obtain a measurable signal across a range of pH values, pre-
sented a unique opportunity to utilise this systems intrinsic
characteristic for the analysis of biological fluids, where
samples with a range of pH values would be encountered.
Biological fluid analysis
The developed [Ru(bpy)3]
2+ sensing platform utilised here for
the analysis of biological fluid samples has previously demon-
strated satisfactory analytical performance,24,27 offering suit-
able detection limits and the required precision, with an elec-
trode reproducibility of 1.9% and repeatability of 8.3%. As
such the designed sensor offers an idea analysis tool for the
screening of biological fluids for illicit substance detection.
Human pooled serum analysis
The dose of scopolamine administered for criminal and preda-
tory use has been reported between 0.99 and 6.23 µM in blood
(0.0003 to 0.00189 mg mL−1), which is approximately 50 to
3000 times the typical therapeutic dose for one dermal slow
release patch administered over a 24 hours period, resulting in
an approximate therapeutic blood concentration of 0.99 nM
(3.0 × 10−7 µg mL−1).15,16,43 Despite the therapeutic concen-
Scheme 1 Mechanism of the oxidative N-dealkylation responsible for
the ECL emission of scopolamine (a), based upon the oxidative
N-dealkylation mechanism of atropine,24 leading to the formation of
norscopolamine (e) and formaldehyde (f).
Fig. 2 Trend in ECL intensity with pH for scopolamine hydrobromide
prepared in 0.1 M LiClO4 at the desired pH. Measurements were col-
lected at a scan rate of 100 mV s−1 across of 0.5 ≤ E ≥ 1.36 V vs. Ag at a
PMT setting of 0.6 V. Each point represents the mean of the maximum
ECL intensity at n = 3 with error bars comprising of ±1 SD across these
measurements.
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tration of approximately 0.99 nM lying outwith the detection
limits achievable with this current screening methodology,
such low concentrations would not induce the adverse symp-
toms which would result in users requiring emergency treat-
ment. As such, there is currently no significant demand for
emergency room screening protocols to operate in the nM
region.
No sample preparation was performed on serum samples,
which were analysed neat. Neat serum was spiked to give a
final concentration of 1 µM scopolamine hydrobromide. Once
serum was spiked with the hallucinogen, this mixture was
then analysed directly upon the modified electrodes. Fig. 3
shows a comparison of the voltammograms obtained with the
ruthenium modified electrodes. Despite the complexity and
likely resistance to charge transfer of neat serum, the voltam-
mograms obtained demonstrate its ability to offer the conduc-
tivity necessary for use as a suitable electrochemical matrix.
This is confirmed through the comparable peak-to-peak separ-
ations of the Ru2+/3+ redox couple within serum and a typical
supporting electrolyte of 0.1 M LiClO4, with ΔEp values of
136 mV for serum and 134 mV in 0.1 M LiClO4 achieved.
Where the difference in the E0, Epa and Epc values is attributed
to the use of the non-isolated quasi-reference electrode com-
prising of screen-printed silver paste.
Analysis of neat serum revealed that species intrinsic to the
matrix were able to behave as suitable co-reactants producing
a measurable signal at potentials similar to that of scopola-
mine. This is not entirely surprising given the complex compo-
sition of serum, containing a wide variety of amino acids and
proteins, which have been previously shown to produce ECL
with the [Ru(bpy)3]
2+ luminophore.44–48 Previous ECL analysis
within extracted and purified serum has demonstrated a
similar ECL response from serum with the [Ru(bpy)3]
2+ lumi-
nophore.49 Further analysis of four of the common amino
acids; proline, tryptophan, glutamine and lysine with the
developed sensor with a supporting electrolyte of LiClO4,
revealed their ability to behave as suitable ECL co-reactants,
refer to Fig. S2.† As such, the specificity of any ruthenium
based ECL sensors’ will be negatively impacted, for biological
fluid analysis, due to the presence of free amino acids.
Although under ideal electrochemical conditions these free
amino acids produced intensities comparable to scopolamine,
when compared to the signal intensity observed for raw serum
(see Fig. 4) there is a significant difference between this and
that of 0.1 µM scopolamine signal. This background response
intrinsic to serum can likely be attributed to the low concen-
tration of free amino acids present within serum, which gener-
ates this response. A brief investigation across six pooled
serum samples demonstrated a degree of variation in the
intrinsic background signal, shown in Fig. S3.† With an RSD
of 17% across pooled serum samples, there is a high likeli-
hood of the background serum response varying across indi-
viduals. This variation could be influence be a person’s health,
whether blood collection was performed fed or fasted or any
medication they are prescribed. This would require a compre-
hensive clinical study to be performed, and although beyond
the scope of this current proof-of-concept study it would be
erroneous to not consider the potential impact this could
have. Although variation was observed across the pooled
serum samples a threshold signal of ∼0.498 A.U. could be
established lying well below the lowest concentration of
0.1 µM analysed at an intensity of ∼1.23 A.U. However, this by
no means represents a true threshold value, as clinical studies
across a range of individuals would be required to establish
this.
Although the use of raw serum as a sample matrix without
performing any prior purification therefore poses an increased
risk of false identification within biological fluids the signifi-
cant visual difference observed between the matrix without the
hallucinogen and with a clinically relevant concentration dis-
plays a strong premise for its use as a screening tool for serum
samples. Screening protocols rely upon qualitative identifi-
cation, a prerequisite met by this proposed methodology. Even
at significantly low scopolamine concentrations at 0.5 µM and
Fig. 3 Typical CV highlighting the Ru2+/3+ redox couple, with compar-
able ΔEp values observed in both 0.1 M LiClO4 (green) and neat serum
(pink) collected at a scan rate of 100 mV s−1 across a potential range of
0.5 ≤ E ≥ 1.5 V vs. Ag. The use of the quasi-reference electrode accounts
for the difference in E0 values.
Fig. 4 ECL responses of neat serum (blue) and 1 µM (green), 0.5 µM
(pink) and 0.1 µM (yellow) scopolamine hydrobromide in human pooled
serum collected with the [Ru(bpy)3]
2+
film modified carbon screen
printed working electrode at a scan rate of 100 mV s−1 across a potential
range of 0.6 ≤ E ≥ 1.5 V vs. Ag and a PMT setting of 480 V.
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0.1 µM, which lie below scopolamine’s LD50 at an approximate
concentration of 6.23 µM,43 an easily identifiable difference
between neat serum and that containing the hallucinogen is
observed, refer to Fig. 4.
Analysis of the ECL signal in Fig. 4 also reveals a shift in
the potential at which the maximum ECL intensity is observed.
This phenomenon is something which has been previously
reported with increasing concentrations of co-reactants at the
ruthenium sensor.24,27 As such, it is likely this observed shift
can be attributed to the two main effects previously
reported;24,27,50 ruthenium becoming the rate limiting reagent
and a pH alternation at the inner Helmholtz plane close to the
electrode surface. As the ruthenium within the sensor
becomes the rate limiting reagent, oxidation of the species
required to produce ECL becomes more difficult with the lumi-
nophore consumed at a rate quicker than it can be produced.
Secondly, as higher concentrations of scopolamine are
present, there is a greater concentration of the oxidative
N-dealkylation by-products, formaldehyde and norscopola-
mine, resulting in a shift in pH at the inner Helmholtz plane.
The signal observed at 0.1 µM lies at the limit of detection
(LOD) of ∼1.29 A.U., where the LOD was determined at 3 times
the blank signal intensity observed from neat serum (with a
serum ECL intensity of ∼0.43 A.U.). As such with a low LOD we
are confident in the sensors ability to operate as a qualitative
screening tool at clinically relevant concentrations.
Despite the frequent use of blood and subsequently serum
for drug detection, the need to separate serum from blood
prior to analysis still poses a significant limitation.
Furthermore, collection of blood from a patient is an invasive
procedure. The extraction of serum from the collected whole
blood matrix, requires time consuming sample preparation,
specialist equipment and expertise. As such this fails to meet
the requirement for point-of-care devices for use by physicians.
Although the ability to overcome this sample preparation step
through the use of whole blood samples offers a possible solu-
tion, the limited penetration of visible light through whole
blood prevents detection of the electrogenerated luminescence
from the ruthenium complex with an emission maximum at
∼625 nm.51
Urine
With limited pharmacological studies on scopolamine avail-
able, little is known regarding its metabolism and excretion
pathways. However current studies do suggest scopolamine
undergoes a first pass metabolism, with ∼5% of the parent
drug renally excreted. As such it was important to assess
sensor performance within this matrix. As with serum no
sample preparation was performed, with all samples analysed
neat in Suirne™ without dilution or purification. In contrast
to serum, urine produced an anodic peak at ∼1.11 V vs. Ag at
the unmodified carbon electrode surface, see Fig. S4.†
Previous electrochemical analysis of urine has displayed a
similar oxidation peak at ∼1.0 V vs. Ag/AgCl 34 and was attribu-
ted to the presence of uric acid, which has previously been
shown to undergo oxidation at carbon electrodes.34,52 The
same anodic peak is observed at the ruthenium modified elec-
trode, at ∼1.16 V vs. Ag, refer to Fig. S4,† and as such obscures
the reversible Ru2+/3+ couple normal observed. The ECL
response of the urine matrix, shown in Fig. 5, displays signifi-
cant background signal from the matrix, comparable to that
observed in serum. Previous analysis of urine via ruthenium
based ECL sensors has demonstrated an intrinsic emission
generated by the matrix,53–55 as such the emission observed
here is not unexpected. Although the presence of uric acid pro-
duced the oxidation peak within the CV, it has been previously
demonstrated that uric acid behaves as an ECL quencher
toward the tripropylamine [Ru(bpy)3]
2+ system and hence it is
not assumed to be responsible for the emission peak observed
within the blank urine.55,56 Similarly, urea and ascorbic acid
have also shown quenching interreference of [Ru(bpy)3]
2+ gen-
erated ECL during urine analysis.55–57 As such it is likely that
the emission intrinsic to the urine matrix is in fact related to
the presence of lactic acid and creatinine, both of which have
previously been shown to produce ECL with ruthenium
luminophores.48,58–60 Scopolamine hydrobromide was spiked
into the urine matrix at a range of clinically relevant concen-
trations from 0.5 to 6 µM. As can be seen within Fig. 5 a dis-
tinct visual difference across all concentrations was apparent,
with 6 µM at an ECL intensity ∼5.3 times that of the blank. In
comparison to the serum matrix, sensitivity was reduced, with
the LOD ten times greater than that of serum. It is thought
this could be related to the competing reactions due to the
presence of the known quenchers of ascorbic acid, urea and
uric acid. However, despite the signals obtained at 0.5 µM and
1 µM being below that of the typical analytical standard of 3
times the blank intensity, if a threshold was established then
if the observed intensity was greater than that of the threshold
the hallucinogen could be qualitatively identified. Initial
studies established the threshold at ∼0.7 V across three elec-
trode measurements. However further investigation would be
warranted to determine whether this value would be affected
by person to person variation from clinical human urine
Fig. 5 ECL responses of urine (blue) and urine spiked with 6 µM
(green), 1 µM (pink) and 0.5 µM (yellow) scopolamine hydrobromide
with the [Ru(bpy)3]
2+
film modified carbon screen printed working elec-
trode at a scan rate of 100 mV s−1 across a potential range of 0.5 ≤ E ≥
1.5 V vs. Ag and a PMT setting of 0.48 V.
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samples. As such, despite urine being one of the most fre-
quently used toxicological samples for drug detection and
negates the requirement for sample extraction, as is required
for serum from whole blood, the reduced sensitivity as a result
of the competing quenching reactions would limit its use as a
point-of-care device in its current format.
Analysis of artificial saliva
A potential alternative biological matrix which could easily be
collected from a patient presenting with symptoms is saliva.
Saliva offers a number of advantages over blood and serum as
a sample matrix. Collection of saliva can be considered less
invasive for patients compared to blood withdrawal or indeed
urine collection. What’s more saliva, unlike blood, would not
require preparation prior to analysis, with visible light able to
easily penetrate through the matrix for analyte detection.
Previous analysis of saliva via ECL have been reported,
however they have required either buffer dilution or incorpor-
ation into an immunoassay format, rather than a direct detec-
tion method, as proposed here.60–63
Compatibility of the proposed ECL sensor for direct saliva
analysis was investigated through the use of artificial saliva,
containing a number of the active enzymes naturally present
within human saliva. Neat artificial saliva did not produce a
significant ECL emission as shown by Fig. 6. This is in contrast
to human serum and urine (refer to Fig. 4 and 5), where as a
result of the free amino acids, lactic acid and creatinine a
notable ECL response from the biological matrix is observed.
This therefore suggests that the enzymes present within saliva
do not behave as suitable co-reactants toward the ruthenium
complex utilised within this sensor design. When the artificial
saliva sample was spiked with high scopolamine concen-
trations at 10 µM, a clear visual difference between the neat
matrix and that which contains the hallucinogen was
observed, refer to Fig. 6. However, this concentration is greater
than what would be clinically observed, as such the concen-
tration was decrease to 1 µM to establish the sensors potential
for clinical translation. Despite this significant concentration
decrease, we can again observe a distinct visual difference
between the blank biological matrix and that containing the
hallucinogen. In contrast to serum, where a LOD of 0.1 µM
was obtained, here the LOD will be approximately ten times
greater, comparable to urine analysis, with the 1 µM intensity
observed at 4 times that of the blank. This poorer sensitivity
within saliva could be attributed to the poorer electron transfer
kinetics within this matrix. Saliva compared to serum has a
higher viscosity. As such, as can be seen through interrogation
of the CV (refer to Fig. S5†), the ruthenium redox couple
display flatter and broader peaks with an increased ΔEp of
399 mV. This increase in ΔEp is likely related to the increased
resistance of the more viscous matrix toward charge transfer.
As such, a large Ohmic drop will be observed, contributing to
the large peak-to-peak separation observed. Thus, with the
poorer kinetics present within this viscous matrix the
decreased sensitivity compared with serum is not surprising.
However, the unmistakable difference in ECL intensity at 1 µM
does nevertheless meet the requirements for use as a qualitat-
ive tool for identification of the hallucinogen within saliva at
clinically relevant concentrations. As such, the ECL sensing
platform within this contribution meets the prerequisites for
use as a saliva screening tool without any pre-treatment or
purification required.
Artificial sweat
With serum, saliva and urine providing suitable matrices for
ECL analysis of biological fluids, the potential for the use of
sweat provided a promising avenue. The ability to use sweat
for drug screening would offer a minimally invasive technique,
which could offer a viable alternative matrix for emergency
room physicians. Patients experiencing significant hallucino-
genic symptoms, under severe distress or intubated due to res-
piratory problems could make the collection of serum, urine
or saliva for physicians challenging, particularly when rapid
answers are required. Thus, sweat which can be easily col-
lected from the skins surface offers a practical alternative. As
with the previous matrices sweat itself did produce a small
signal, likely related to the presence of the different biological
and salt components, including lactic acid previously reported
to produce an ECL emission.64–66
Fig. 7 shows the ECL response observed when scopolamine
was present within artificial sweat at a concentration of 10 µM.
Comparable to that observed within saliva, a significant differ-
ence between the neat matrix and that containing the halluci-
nogen was observed. Furthermore, when the concentration
was decreased to the clinically relevant concentration of 1 µM,
a distinct visual difference at an intensity 3.4 times greater
than the blank matrix signal allowed for clear differentiation
between the intrinsic matrix signal and that of the hallucino-
gen. As such, this methodology allowed for confident identifi-
cation of scopolamine within sweat. However, prior to
implementation as a point-of-care device it would be necessary
to establish a threshold signal which would account for person
to person variation and any further potential interferents as a
Fig. 6 ECL responses of artificial saliva (blue) and artificial saliva spiked
with 10 µM (pink) and 1 µM (yellow) scopolamine hydrobromide with
the [Ru(bpy)3]
2+
film modified carbon screen printed working electrode
at a scan rate of 100 mV s−1 across a potential range of 0.5 ≤ E ≥ 1.3 V
vs. Ag and a PMT setting of 480 V.
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result of the consumption of medications, alcohol or any
others substances a patient may have taken or applied to their
skin. As such, to confidently establish such a threshold value
further investigation is warranted.
To obtain the signals shown in Fig. 7(a) a casting volume of
100 µL was employed. However, in reality the volume of sweat
which would be collected off an individual’s skin would be far
less. A wearable or surface applied sensor would offer the most
appropriate system for future point-of-care devices and would
also facilitate continuous real time patient monitoring. To
determine the feasibility of this sensor design for incorpor-
ation into a wearable device, the sensor was assessed for the
collection and detection of scopolamine off synthetic skin. To
perform these measurements synthetic skin was either soaked
in blank sweat or sweat spiked with scopolamine for approxi-
mately 30 minutes, after which the skin was then removed.
The skin coated with the sweat was then placed within a petrie
dish to provide a flat surface to facilitate the mechanical
wiping of the modified electrode. The electrode was slowly
wiped across the surface of the skin by hand a total of three
times to collect the sample, visually ensuring full electrode
coverage prior to analysis. The geometry of the SPE is ideal for
such applications due to the close proximity of all three elec-
trodes, with a total area of ∼33 mm2 requiring sample cover-
age. While the flexible polymer support allows for the elec-
trode to be manipulated with ease avoiding any damage to the
electrode surfaces during this process. Despite a significant
reduction in the volume of sample present upon the electrode
surface, as can be seen within Fig. 7(b), the sample containing
the hallucinogen can still be confidently identify from the
blank sweat, with a signal intensity ∼47 times greater that of
the blank sweat.
As such, this presents a strong proof-of-concept for the
developed ECL sensor for employment as a wearable point-of-
care device, however further investigation is again warranted
to established whether the reported design is appropriate for
clinical translation. Preferably human trials would offer the
greatest understanding and knowledge regarding potential
clinical translation. However, the toxicity of scopolamine and
potential side effects at the required levels would prevent such
trials, in turn preventing the attainment of genuine sweat
samples from human skin following indigestion, metabolism
and execration of the drug. Nevertheless, the successful use of
ruthenium based ECL sensors for the analysis of human sweat
on skin and off surfaces have been recently reported,65,66 and
as such provides us with a degree of confidence that the pro-
posed sensor within this contribution would be fundamentally
viable for clinical use.
Conclusions
A portable electrochemilunescent sensor has been successfully
developed for the detection of tropane alkaloid scopolamine
within a variety of complex biological matrices. Utilising dispo-
sable screen-printed electrodes modified with a simple Nafion-
[Ru(bpy)3]
2+ film, a low-cost alternative to the complex instru-
mentation currently utilised for analysis of such samples is
offered. Here we propose a timely qualitative sensor for screen-
ing of the consumption of non-traditional drugs, such as novel
psychoactive substances, alongside common illicit substances
which may be encountered within an hospital emergency
room. Within such clinical environments an easily obtained
and rapid “yes or no” answer is often required, a criterion met
by our proposed methodology. Despite the complex nature of
matrices such as serum, urine, saliva and sweat, we did not
observe any significant interference effects which negatively
impacted upon our qualitative analysis at clinically relevant
concentrations. As such we were able to confidently identify
between neat matrices and those containing the hallucinogen.
What’s more, we have been able to remove the requirement for
complex, time-consuming and costly sample extraction pro-
cedures which would require specialist facilities and knowl-
edgeable experts in variety of sample extraction techniques.
Further to this, we have developed a simplistic sensing system
capable of detecting low volumes of a species from a biological
surface such as artificial skin. The proof-of-concept demon-
Fig. 7 (a) ECL responses of artificial sweat (blue) and artificial sweat
spiked with 10 µM (pink) and 1 µM (yellow) scopolamine hydrobromide
with the [Ru(bpy)3]
2+
film modified carbon screen printed working elec-
trode at a scan rate of 100 mV s−1 across a potential range of 0.5 ≤ E ≥
1.36 V vs. Ag and a PMT setting of 480 V. (b) ECL responses of artificial
sweat (green) and artificial sweat spiked with scopolamine hydrobro-
mide (pink) collected off synthetic skin via mechanical wiping of the [Ru
(bpy)3]
2+
film modified carbon screen printed working electrode col-
lected at a scan rate of 100 mV s−1 across a potential range of 0.5 ≤ E ≥
1.36 V vs. Ag and a PMT setting of 600 V.
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strated within this contribution is strong, however further
testing of the sensor is warranted. Although this contribution
only discusses the identification of scopolamine, previous
reports have demonstrated how this sensor alongside similar
systems have been employed for the detection of other structu-
rally similar amines, including atropine and
methamphetamine.24,27,29 As such, this sensor could be
applied for the detection of species other than scopolamine
within these biological matrices with ease. However, this also
proposes a question of potential interreference effects from
structurally similar species. Further investigations into the
impact of other commonly consumed substances such as
medication, nicotine or alcohol would therefore also be perti-
nent. Current investigations into the ability to negate the inter-
ference effects from structurally similar species such as amino
acids and atropine is on-going, and includes examination of
alternative metal luminophores, with preliminary results
suggesting the ability to switch off emission from interfering
species is possible. While the ability to differentiate between
species via pH controlled ECL has been previously demon-
strated.24 Ultimately, enhancing the specificity of the sensor
would only stand to improve its design and hence increase its
potential toward clinical translation. Current analysis has been
performed on simulated scenarios utilising artificial sweat,
skin and saliva. In order to gain a greater understanding of the
applicability of the current sensor design for employment
within patient care it would be necessary to test the sensor
upon clinical samples obtained following scopolamine con-
sumption. The toxicity of scopolamine makes testing of the
sensor under real-world conditions challenging. To combat
this, there is the potential to utilise more commonly encounter
species which produce ECL emission within the same region.
We have previously reported that compounds with structural
similarities, such as sister tropane alkaloid atropine, produce
similar ECL signals within the same potential region.23,24 As
such the use of a structurally similar species such as nicotine,
another alkaloid known to produce an ECL signal within
sweat66 could offer a viable solution. Allowing for the assess-
ment of additional interferent effects on the sensor due to
other components excreted within sweat or saliva not con-
sidered within this current contribution. Nevertheless, the
current sensor design within the contribution demonstrates a
promising avenue toward the expansion of ECL based sensors
as point-of-care devices.
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